Recent advances in the prevention of mother-to-child transmission

Current Opinion in HIV and AIDS

Volumn 3, Issue 2, 2008, Pages 136-138

  McIntyre, James ^a   Lallemant, Marc ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Institute of research for development Thailand   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; EDITORIAL; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; MOTHER CHILD RELATION; NONHUMAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 40049092294     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f5243c     Document Type: Editorial

References (25)

1. Sansom SL, Harris NS, Sadek R, et al. Toward elimination of perinatal human immunodeficiency virus transmission in the United States: effectiveness of funded prevention programs, 1999-2001. Am J Obstet Gynecol 2007; 197(3 Suppl):S90-S95.
2. Harris NS, Fowler MG, Sansom SL, et al. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. Am J Obstet Gynecol 2007; 197 (3 Suppl):S33-S41.
3. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. Geneva: World Health Organization; 2007.
4. Sripipatana T, Spensley A, Miller A, et al. Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol 2007; 197 (3 Suppl):S107-S112.
5. Luzuriaga K, Newell ML, Dabis F, et al. Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet 2006; 368:511-521.
6. National Institutes of Health. Immunizations are discontinued in two HIV vaccine trials; 21 September 2007. http://www3.niaid.nih.gov/news/newsreleases/ 2007/step_statement.htm. (Accessed 1 December 2007)
7. STEP study: disappointing, but not a failure. Lancet 2007; 370:1665.
8. Fowler MG, Lampe MA, Jamieson DJ, et al. Reducing the risk of mother-tochild human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 2007; 197 (3 Suppl):S3-S9.
9. McConnell MS, Stringer JS, Kourtis AP, et al. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 2007; 197 (3 Suppl):S56-S63.
10. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007; 21:957-964.
11. Flys TS, Mwatha A, Guay LA, et al. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS 2007; 21:2077-2082.
12. Kuhn L, Sinkala M, Kankasa MP, et al. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr 2006; 42:260-262.
13. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: World Health Organization; 2006.
14. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007; 197 (3 Suppl):S42-S55.
15. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet 2007; 370:1668-1670.
16. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
17. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924.
18. McKenna MT, Hu X. Recent trends in the incidence and morbidity that are associated with perinatal human immunodeficiency virus infection in the United States. Am J Obstet Gynecol 2007; 197 (3 Suppl):S10-S16.
19. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519-526.
20. Wilfert CM, Fowler MG. Balancing maternal and infant benefits and the consequences of breast-feeding in the developing world during the era of HIV infection. J Infect Dis 2007; 195:165-167.
21. Mataka E. Maternal health and HIV: bridging the gap. Lancet 2007; 370:1290-1291.
22. Abrams EJ, Myer L, Rosenfield A, El-Sadr WM. Prevention ofmother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. Am J Obstet Gynecol 2007; 197 (3 Suppl): S101-S106.
23. WHO. Strategic approaches to the prevention of HIV infection in infants. Report of a WHO meeting; Morges, Switzerland; 20-22 March 2002. Geneva: World Health Organization; 2002.
24. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144.e1-144.e8.
25. Morrison CS. Commentary: Hormonal contraception and HIV acquisition: current evidence and ongoing research needs. Int J Epidemiol 2007; 36:175-177.